Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903)
Authors:
- written on Henan Cancer Hospital Thoracic Oncology Group (HCHTOG)W(written on Henan Cancer Hospital Thoracic Oncology Group (HCHTOG)
- Wen-Qun XingWXWen-Qun Xing
Open Access
- 15 April 2020
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-8
Abstract
Background: Neoadjuvant therapy plus oesophagectomy has been accepted as the standard treatment for patients with potentially curable locally advanced oesophageal cancer. No completed randomized controlled trial (RCT) has directly compared neoadjuvant chemotherapy and neoadjuvant chemoradiation in patients with oesophageal squamous cell carcinoma (ESCC). The aim of the current RCT is to investigate the impact of neoadjuvant chemotherapy plus surgery and neoadjuvant chemoradiotherapy plus surgery on overall survival for patients with resectable locally advanced ESCC.Methods: This open label, single-centre, phase III RCT randomized patients (cT2-T4aN + M0 and cT3-4aN0M0) in a 1:1 fashion to receive either the CROSS regimen (paclitaxel 50 mg/m2; carboplatin (area under the curve = 2), q1w, 5 cycles; and concurrent radiotherapy, 41.4 Gy/23 F, over 5 weeks) or neoadjuvant chemotherapy (paclitaxel 175 mg/m2; and cisplatin 75 mg/m2, q21d, 2 cycles). Assuming a 12% 5-year overall survival difference in favour of the CROSS regimen, 80% power with a two-sided alpha level of 0.05 and a 5% dropout each year for an estimated 3 years enrolment, the power calculation requires 456 patients to be recruited (228 in each group). The primary endpoint is 5-year overall survival, with a minimum 5-year follow-up. The secondary endpoints include 5-year disease-free survival, toxicity, pathological complete response rate, postoperative complications, postoperative mortality and quality of life. A biobank of pre-treatment and resected tumour tissue will be built for translational research in the future.Discussion: This RCT directly compares a neoadjuvant chemotherapy regimen with a standard CROSS regimen in terms of overall survival for patients with locally advanced ESCC. The results of this RCT will provide an answer for the controversy regarding the survival benefits between the two treatment strategies.Trial registration: NCT04138212, date of registration: October 24, 2019.Keywords
Funding Information
- Health Committee of Henan Province (SB201901108)
This publication has 26 references indexed in Scilit:
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerNew England Journal of Medicine, 2012
- A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)Annals of Surgical Oncology, 2011
- Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal CancerJournal of Clinical Oncology, 2009
- Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric JunctionJournal of Clinical Oncology, 2009
- Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal CancerJournal of Clinical Oncology, 2007
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trialThe Lancet, 2002
- Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal CancerNew England Journal of Medicine, 1998
- A Comparison of Multimodal Therapy and Surgery for Esophageal AdenocarcinomaNew England Journal of Medicine, 1996